Chunqin Deng
Overview
Explore the profile of Chunqin Deng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Saggar R, Giri P, Deng C, Johnson D, McCloy M, Liang L, et al.
Pulm Circ
. 2021 May;
11(2):20458940211011329.
PMID: 33996029
The association of autoimmune disease (AI) with transplant-free survival in the setting of Group 3 pulmonary hypertension and pulmonary fibrosis remains unclear. We report cases of severe pulmonary hypertension (mean...
12.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, et al.
N Engl J Med
. 2021 Jan;
384(4):325-334.
PMID: 33440084
Background: No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition...
13.
Chin R, Deng C, Bril V, Hartung H, Merkies I, D Donofrio P, et al.
Muscle Nerve
. 2015 Mar;
52(4):498-502.
PMID: 25728021
Introduction: Electrodiagnostic studies (EDX) are not performed routinely before treatment suspension in CIDP, and no data exist regarding their value in predicting clinical relapse. Methods: Serial EDX (baseline and after...
14.
Deng C, Hanna K, Bril V, Dalakas M, Donofrio P, van Doorn P, et al.
J Neurol
. 2011 Aug;
259(2):348-52.
PMID: 21822934
Clinical equipoise is widely accepted as the basis of ethics in clinical research and requires investigators to be uncertain of the relative therapeutic merits of trial comparators. When clinical equipoise...
15.
Merkies I, Hughes R, Donofrio P, Bril V, Dalakas M, Hanna K, et al.
J Peripher Nerv Syst
. 2010 Nov;
15(3):208-15.
PMID: 21040143
A randomized trial (ICE trial) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) demonstrated significantly more improvement with intravenous immunoglobulin (Gamunex(®), Talecris Biotherapeutics, Inc., Research Triangle Park, NC) than placebo. To understand...
16.
D Donofrio P, Bril V, Dalakas M, Deng C, Hanna K, Hartung H, et al.
Arch Neurol
. 2010 Sep;
67(9):1082-8.
PMID: 20837852
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a common inflammatory neuropathy that can be progressive, stepwise progressive, or relapsing and remitting. Objectives: To further evaluate the long-term safety and tolerability...
17.
Bril V, Banach M, Dalakas M, Deng C, Donofrio P, Hanna K, et al.
Muscle Nerve
. 2010 Jul;
42(4):492-7.
PMID: 20665514
Data are lacking on correlations between changes in nerve conduction (NC) studies and treatment response in chronic inflammatory demyelinating polyneuropathy (CIDP). This report examined data from a randomized, double-blind trial...
18.
Latov N, Deng C, Dalakas M, Bril V, Donofrio P, Hanna K, et al.
Arch Neurol
. 2010 May;
67(7):802-7.
PMID: 20457948
Objective: To investigate the timing, course, and clinical characteristics of the response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Design: Data were extracted from the ICE trial, a...
19.
Parr D, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley R
Respir Res
. 2009 Aug;
10:75.
PMID: 19678952
Background: Computed tomography (CT) lung densitometry has been demonstrated to be the most sensitive and specific outcome measure for the assessment of emphysema-modifying therapy, but the optimum densitometric index has...
20.
Bril V, Katzberg H, Donofrio P, Banach M, Dalakas M, Deng C, et al.
Muscle Nerve
. 2009 Mar;
39(4):448-55.
PMID: 19260050
Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) received immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C, Gamunex; n=59) or placebo (n=58) every 3 weeks for up to 24 weeks (first period)...